Huang Xinjie, Peng Chunhui, Chen Yajun, Wu Dongyang, Chen Wei, Wang Zengmeng, Wang Kai
Department of General Surgery, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, No. 56 Nanlishi Road, Beijing, 100045, China.
Department of Pediatric Surgery, Beijing Tsinghua Changgung Hospital, No.168 Litang Road, Beijing, 102218, China.
BMC Pediatr. 2025 May 19;25(1):404. doi: 10.1186/s12887-025-05760-z.
Biliary obstruction is a rare complication in patients with hereditary spherocytosis (HS). The clinical course and optimal treatment strategies for HS patients complicated by biliary obstruction remain unclear.
We conducted a retrospective review of 16 pediatric HS patients complicated by biliary obstruction who were treated at our hospital between January 2018 and October 2024. Based on previously published clinical severity classifications, patients were divided into Group A (non-severe group: trait, mild, and moderate) and Group B (severe group).
The study included 16 patients with a mean age of 9.0 ± 3.2 years, evenly distributed between the two groups (8 patients each). Preoperative routine blood tests showed no significant differences between the groups; however, Group B exhibited higher bilirubin levels and lower liver enzyme levels. Genetic testing was performed in 12 patients, revealing SPTB gene mutations in 7 (58.3%). Conservative management effectively resolved biliary obstruction in 10 patients (62.5%) within 14 days. Invasive interventions, such as endoscopic retrograde cholangiopancreatography (ERCP) or cholecystostomy, were required in 6 patients, with conjugated bilirubin levels normalizing within five days post-procedure. Complications occurred in two patients with prolonged intervals between diagnosis and surgery (> 3 months): one required stent replacement due to blockage after ERCP, and the other developed a gallbladder-skin fistula and coagulation disorder following laparoscopic cholecystostomy. Of the 14 patients who underwent subsequent splenectomy and/or cholecystectomy, 12 recovered without complications. Notably, the 6 patients who underwent splenectomy alone without cholecystectomy did not experience biliary colic during a mean follow-up period of 3.4 years (range: 0.5 - 5.5 years).
Biliary obstruction can complicate HS in pediatric patients regardless of anemia severity, particularly in those with SPTB gene mutations. Conservative management is effective in most cases, while invasive procedures are required for refractory cases. Shortening the interval between diagnosis and subsequent surgery may help prevent complications. Splenectomy alone appears to be a viable option once biliary obstruction is resolved.
胆道梗阻是遗传性球形红细胞增多症(HS)患者中一种罕见的并发症。HS合并胆道梗阻患者的临床病程及最佳治疗策略仍不明确。
我们对2018年1月至2024年10月在我院接受治疗的16例合并胆道梗阻的儿科HS患者进行了回顾性研究。根据先前发表的临床严重程度分类,将患者分为A组(非严重组:特征型、轻度和中度)和B组(严重组)。
该研究纳入16例患者,平均年龄9.0±3.2岁,两组患者数量均衡(每组8例)。术前常规血液检查显示两组之间无显著差异;然而,B组的胆红素水平较高,肝酶水平较低。对12例患者进行了基因检测,其中7例(58.3%)检测到SPTB基因突变。保守治疗使10例患者(62.5%)在14天内有效缓解了胆道梗阻。6例患者需要进行侵入性干预,如内镜逆行胰胆管造影(ERCP)或胆囊造瘘术,术后5天内结合胆红素水平恢复正常。2例诊断与手术间隔时间较长(>3个月)的患者出现了并发症:1例患者因ERCP后堵塞需要更换支架,另1例患者在腹腔镜胆囊造瘘术后出现胆囊皮肤瘘和凝血障碍。在随后接受脾切除术和/或胆囊切除术的14例患者中,12例康复且无并发症。值得注意的是,6例仅接受脾切除术而未行胆囊切除术的患者在平均3.4年(范围:0.5 - 5.5年)的随访期内未出现胆绞痛。
无论贫血严重程度如何,胆道梗阻都可能使儿科HS患者病情复杂化,尤其是那些存在SPTB基因突变的患者。在大多数情况下,保守治疗是有效的,而难治性病例则需要进行侵入性手术。缩短诊断与后续手术之间的间隔时间可能有助于预防并发症。一旦胆道梗阻得到解决,单纯脾切除术似乎是一个可行的选择。